Eli Lilly Sues Generic Drug Co. Over Gemzar Patents

Law360, New York (October 31, 2006, 12:00 AM EST) -- Pharmaceutical company Eli Lilly & Co. has targeted a generic drug company in a patent infringement suit related to its top-selling cancer treatment Gemzar.

Eli Lilly brought the suit last week against Mayne Pharma, a Paramus, N.J.-based company that markets generic and specialty injectable drug products, in the U.S. District Court for the Southern District of Indiana.

The Indianapolis, Ind.-based drug maker claimed that Mayne violated two of its patents by filing an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration to...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.